Anticancer research · 2016
Teratogenic Effect of Radotinib: Case Report.
Источник пометил эту публикацию как отозванную.
Клинический случайСтатьяОтозванная публикацияНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Cheon Juyoung, Ahn Jung Whan, Park Kyung Min, Lee Guisera, Jo Yun Sung
Аннотация
BACKGROUND: Simultaneous presentation of pregnancy and chronic myeloid leukemia (CML) is rare. Tyrosine kinase inhibitors (TKIs) are rarely used in pregnancy. There is almost no information on the effect of recently developed TKIs on the fetus.
CASE REPORT: A 22-year-old woman became pregnant while using radotinib, a novel TKI for CML. She was concerned about the possible teratogenic effect of radotinib; hence the first pregnancy was terminated. The patient underwent full-term delivery at the second pregnancy. The infant had facial deformity and congenital laryngomalacia.
CONCLUSION: We witnessed structural abnormality when the patient used radotinib during the first trimester of pregnancy. When radotinib is prescribed for women of childbearing age, thorough education about contraception is necessary.
CASE REPORT: A 22-year-old woman became pregnant while using radotinib, a novel TKI for CML. She was concerned about the possible teratogenic effect of radotinib; hence the first pregnancy was terminated. The patient underwent full-term delivery at the second pregnancy. The infant had facial deformity and congenital laryngomalacia.
CONCLUSION: We witnessed structural abnormality when the patient used radotinib during the first trimester of pregnancy. When radotinib is prescribed for women of childbearing age, thorough education about contraception is necessary.